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Objective: Assess the efﬁ  cacy of duloxetine 60/120 mg (N = 162) once daily compared 
with placebo (N = 168) in the treatment of patients with ﬁ  bromyalgia, during six months of 
treatment.
Methods: This was a phase-III, randomized, double-blind, placebo-controlled, parallel-group 
study assessing the efﬁ  cacy and safety of duloxetine.
Results: There were no signiﬁ  cant differences between treatment groups on the co-primary 
efﬁ  cacy outcome measures, change in the Brief Pain Inventory (BPI) average pain severity 
from baseline to endpoint (P = 0.053) and the Patient’s Global Impressions of Improvement 
(PGI-I) at endpoint (P = 0.073). Duloxetine-treated patients improved signiﬁ  cantly more than 
placebo-treated patients on the Fibromyalgia Impact Questionnaire pain score, BPI least pain 
score and average interference score, Clinical Global Impressions of Severity scale, area under 
the curve of pain relief, Multidimensional Fatigue Inventory mental fatigue dimension, Beck 
Depression Inventory-II total score, and 36-item Short Form Health Survey mental component 
summary and mental health score. Nausea was the most common treatment-emergent adverse 
event in the duloxetine group. Overall discontinuation rates were similar between groups.
Conclusions: Although duloxetine 60/120 mg/day failed to demonstrate signiﬁ  cant improve-
ment over placebo on the co-primary outcome measures, in this supportive study, duloxetine dem-
onstrated signiﬁ  cant improvement compared with placebo on numerous secondary measures.
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Introduction
Fibromyalgia is a chronic pain disorder characterized by widespread pain, tenderness, 
fatigue, sleep difﬁ  culties, and stiffness.1–3 Fibromyalgia occurs in about 2% of the 
general population of the United States and is more prevalent in women (estimated at 
3.4% to 10.5%) than in men (0.5%).4,5
Serotonin and norepinephrine have been implicated in the mediation of endogenous 
analgesic mechanisms via the descending inhibitory pain pathways in the brain and 
spinal cord.6,7 An imbalance in these inhibitory mechanisms may contribute to central 
sensitization and hyperexcitability of the spinal and supraspinal pain-transmitting path-
ways. This imbalance may manifest as persistent pain.8 Dysfunction in both serotonin 
and norepinephrine systems has been implicated in the etiology of ﬁ  bromyalgia.9–12 
Drugs often administered to treat ﬁ  bromyalgia include analgesics,13 nonsteroidal anti-
inﬂ  ammatory agents,14 sedatives,15 antidepressants,16 and selective serotonin reuptake 
inhibitors.17 In a 12-week trial, the serotonin and norepinephrine reuptake inhibitor 
milnacipran was shown to relieve ﬁ  bromyalgia symptoms at a dose of 200 mg.18
Duloxetine hydrochloride (Cymbalta®) is a selective serotonin and norepineph-
rine reuptake inhibitor that is relatively balanced in its afﬁ  nity for both serotonin and International Journal of General Medicine 2008:1 92
Chappell et al
norepinephrine reuptake inhibition. Preclinical models of 
central sensitization suggest that duloxetine will have efﬁ  -
cacy in the treatment of persistent/chronic pain. In rodents, 
duloxetine has demonstrated efﬁ  cacy in the formalin and 
capsaicin models of persistent pain, as well as in the partial 
sciatic nerve ligation19 and L5/L6 spinal nerve ligation mod-
els of neuropathic pain.20 Patients with ﬁ  bromyalgia have 
quantitatively altered nociception compared with pain-free 
patients, suggesting that people with ﬁ  bromyalgia process 
sensory information differently, most likely due to changes 
in the central processing of pain at the spinal level.21 Current 
knowledge of ﬁ  bromyalgia as a persistent pain condition due 
to central sensitization, along with the efﬁ  cacy of duloxetine 
in preclinical analgesic models of central sensitization, 
suggests that duloxetine will have efﬁ  cacy in the treatment 
of ﬁ  bromyalgia.
Duloxetine is efﬁ  cacious in the treatment of the painful 
physical symptoms associated with depression22 and the 
pain associated with diabetic neuropathy in nondepressed 
patients.23,24 Two double-blind, placebo-controlled, 12-week 
clinical trials of duloxetine have demonstrated its efﬁ  cacy in 
patients with ﬁ  bromyalgia with and without major depressive 
disorder (MDD). The ﬁ  rst study25 examined the safety and 
efﬁ  cacy of duloxetine 60 mg twice daily (BID) in male and 
female patients and the second study26 evaluated duloxetine 
60 mg once daily (QD) and 60 mg BID in female patients.26 
The ﬁ  rst study showed a signiﬁ  cant effect on reduction of 
pain in women but not in men. The small number of men in 
the study (N = 25) may explain the unexpected discrepancy 
between results in men and women.
On the basis of the evidence that duloxetine (60 mg QD 
and/or 60 mg BID) was safe and efﬁ  cacious in the treatment 
of ﬁ  bromyalgia for 12 weeks,25,26 the following trial was 
conducted to assess the efﬁ  cacy in pain reduction, as well as 
safety, of duloxetine 60/120 mg QD compared with placebo 
during six months of therapy.
Methods
Overview
This multicenter study (F1J-MC-HMEF) was conducted in 
36 study centers in Germany, Spain, Sweden, the United 
Kingdom, and the United States. The study settings included 
outpatients from private practices and university clinics. 
Enrollment began in September 2005, and the study was 
completed in December 2006. Each site’s Institutional 
Review Board approved the protocol, and all patients 
provided written informed consent before study procedures 
were initiated.
Entry criteria
Patients were eligible for the study if they were  18 years 
of age and met criteria for ﬁ  bromyalgia as deﬁ  ned by the 
American College of Rheumatology (ACR),1 with or without 
MDD. Exclusion criteria included: current or previous treat-
ment with duloxetine; any current primary Axis I diagnosis 
other than MDD (deﬁ  ned by the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition); pain symptoms 
related to traumatic injury, structural rheumatic disease, or 
regional rheumatic disease (such as osteoarthritis, bursitis, 
tendonitis); regional pain syndrome; multiple surgeries or failed 
back syndrome; conﬁ  rmed current or previous diagnosis of 
rheumatoid arthritis, inﬂ  ammatory arthritis, infectious arthritis, 
or an autoimmune disease; and serious medical illness.
Study design
This was a phase-III, parallel, double-blind, placebo-controlled 
study of patients who met the ACR criteria for ﬁ  bromyalgia.1 
The study design is illustrated in Figure 1. Patients were 
randomly assigned to either duloxetine 60 mg QD or placebo 
in a 1:1 ratio. Assignment to treatment groups was determined 
by a computer-generated random sequence within each study 
center, stratiﬁ  ed by MDD status (yes, no).
Following the one-week screening phase, patients were 
treated in a double-blind manner for 27 weeks. Patients 
randomly assigned to the duloxetine 60 mg QD treatment 
group underwent a titration in which they received duloxetine 
30 mg QD for one week before receiving duloxetine 60 mg 
QD for 12 weeks. If at Visit 8 (Week 13) the patient did not 
have  50% reduction in the Brief Pain Inventory-Modiﬁ  ed 
Short Form (BPI)27 average pain score, the patient was 
blindly escalated to 120 mg QD. If the patient could not 
tolerate this dose, the patient was allowed to return to the 
60-mg dose. Patients were allowed to increase their dose to 
120 mg any time between Visits 8 and 10 (Weeks 13 and 23), 
based upon whether they had  50% reduction in their BPI 
average pain score. If at any time between Visits 9 and 11 
(Weeks 18 and 27) the patient had tolerability issues with 
the higher dose (120 mg QD), the patient was allowed to go 
back to the lower dose (60 mg QD).
Outcome measures
Co-primary efﬁ  cacy outcome measures
Reduction of pain severity was measured by the change in 
the average pain item of the BPI27 from baseline to endpoint; 
patient-reported improvement was assessed by the Patient’s 
Global Impressions of Improvement (PGI-I) questionnaire28 
at endpoint.International Journal of General Medicine 2008:1 93
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Secondary efﬁ  cacy measures
The Fibromyalgia Impact Questionnaire (FIQ)29 is a self-
administered questionnaire that measures fibromyalgia 
patient status, progress, and outcomes over the past week. 
The total score ranges from 0 to 80. A higher score indicates 
a more negative impact. The Clinical Global Impressions 
of Severity (CGI-Severity)28 scale evaluated the severity 
of illness at the time of assessment. The score ranges from 
1 (normal, not at all ill) to 7 (among the most extremely 
ill patients). The CGI-Severity is administered by a study 
physician (blinded to study treatment) in the presence of the 
patient. The tender point pain threshold30 was assessed using 
a dolorimeter for all 18 tender points by a study physician or 
qualiﬁ  ed study personnel (blinded to study treatment), and the 
mean of the thresholds and the number of tender points with 
a low threshold ( 4 kg/cm2) were evaluated. The area under 
the curve (AUC) of pain relief was derived from the BPI 
average pain score.27 The BPI severity score (worst pain, least 
pain, average pain in the past 24 hours, pain right now) and 
average interference pain score are self-reported subscales 
that measure the severity of pain and the interference of pain 
on function. The severity scores range from 0 (no pain) to 
10 (pain as bad as you can imagine). The interference scores 
range from 0 (does not interfere) to 10 (completely interferes) 
and include seven questions assessing the interference of 
pain in the past 24 hours for general activity, mood, walking 
ability, normal work, relations with other people, sleep, and 
enjoyment of life. The Multidimensional Fatigue Inventory 
(MFI)31 is a 20-item, self-report instrument designed to 
collect data on the following dimensions: general fatigue, 
physical fatigue, mental fatigue, reduced motivation, and 
reduced activity. Each dimension is calculated as the sum 
of four statements regarding fatigue on a 0 to 5 scale, and 
thus, the score ranges between 0 and 20, with a higher score 
indicating a higher degree of fatigue. The 17-item Hamilton 
Depression Rating Scale (HAMD17)32,33 is a widely used 
observational rating measure of depression severity and its 
improvement during the course of therapy. The HAMD17 
total score ranges from 0 (not at all depressed) to 52 (severely 
depressed). The Beck Depression Inventory-II (BDI-II)34 
is a 21-item patient-completed questionnaire designed to 
assess characteristics of depression. Each item is rated on a 
four-point scale (0 = not present; 3 = present in the extreme). 
The total score ranges from 0 to 63; the higher the score, the 
more severe the depressive symptoms.
Health outcome and quality
of life measures
These included the patient-rated Sheehan Disability Scale 
(SDS),35 the 36-item Short Form Health Survey (SF-36)36 and 
the European Quality-of-Life Questionnaire – 5 Dimensions 
(EQ-5D).37
Safety
The safety and tolerability of duloxetine were assessed by 
evaluation of spontaneously reported adverse events, reasons 
for discontinuation, laboratory tests (hematology, clinical 
chemistry, lipids), vital signs, weight, and electrocardio-
grams (ECG).
Statistical analysis
This study required the enrollment of 320 patients to have 
at least 80% power to detect a treatment group difference 
of −1.2 points in the baseline-to-endpoint mean change in 
BPI average pain score between duloxetine 60/120 mg QD 
and placebo, assuming a common standard deviation (SD) 
of 2.90, and the treatment group difference of 0.69 with a 
common SD of 1.68 for the endpoint PGI-I score. In the 
sample size calculation, a two-sided test with a signiﬁ  cance 
level of 0.05 and a discontinuation rate of 40% were used.
All analyses were conducted on an intent-to-treat (ITT) 
basis. An ITT analysis is an analysis of data by the groups 
to which patients were assigned by random allocation, even 
if the patient did not take the assigned treatment, did not 
receive the correct treatment, or otherwise did not follow 
the protocol. All analyses, except response at endpoint 
based on  30% reduction in the BPI average pain score, 
were deﬁ  ned a priori (before unblinding) in the protocol or 
statistical analysis plan. Treatment effects were evaluated 
based on a two-sided signiﬁ  cance level of 0.05 and interac-
tion effects at a signiﬁ  cance level of 0.10. No adjustments 
Visit
1
–1
Week
3 to 9 days Weekly Biweekly Every 5 weeks 4 Weeks
23 5 6 9 1 0 1 1
27 23 18 13 8 6 4 2 1 0
78 4
All Patients
No Study Drug
Screening Phase Double-blind Therapy phase
Duloxetine 60 mg QD Duloxetine 60/120 mg QD
Duloxetine 30 mg QD
Placebo
Figure 1 Study design.International Journal of General Medicine 2008:1 94
Chappell et al
for multiple comparisons were made. Unless otherwise 
speciﬁ  ed, when a total score was calculated from individual 
items, it was considered missing if any of the individual items 
were missing. For the SDS item of “work,” if a patient had 
not worked/studied at all during the past week for reasons 
unrelated to the disorder, this item was imputed by using 
the mean score from the other two items of the SDS for that 
patient. When a mean score was computed from individual 
items, it was calculated from existing values.
An analysis-of-covariance (ANCOVA) model was the 
primary analytic method used to analyze continuous efﬁ  cacy 
variables, overall and within subgroups, where the model 
contained the main effects of treatment and investigator, with 
the baseline score as a covariate (Patient’s Global Impressions 
of Severity [PGI-S] for the analysis of the PGI-I). The treat-
ment-by-investigator interaction was tested using a separate 
ANCOVA. When the interaction was statistically signiﬁ  cant, 
the nature of the interaction was explored, but the treatment 
effect was evaluated using the model without the interaction 
term. The consistency of the effect of duloxetine compared 
with placebo on the BPI average pain score in patient sub-
groups of age ( 65,  65), sex, race (Caucasian, other), 
major depressive disorder (yes, no), secondary diagnosis of 
anxiety (yes, no), and previous antidepressant use (yes, no) 
was investigated by adding the relevant subgroup and treat-
ment-by-subgroup interaction terms to the ANCOVA model. 
Continuous demographic and baseline data, vital signs, ECG 
intervals and heart rate, and ranked laboratory data were 
analyzed using an analysis-of-variance (ANOVA) model 
that contained the main effects of treatment and investiga-
tor. Type II sums-of-squares for the least-squares (LS) mean 
were used for the statistical comparison using ANOVA or 
ANCOVA. Categorical variables were compared between 
treatment groups using Fisher’s exact test.
Some efﬁ  cacy variables measured repeatedly over time 
were analyzed using a likelihood-based mixed-effects model 
repeated measures (MMRM) approach,38 to better understand 
the time proﬁ  le of response. The MMRM analyses use like-
lihood-based estimation, and subject-speciﬁ  c effects. Cor-
relations between repeated measures are developed through 
the within-subject error correlation structure. The model 
included the ﬁ  xed categorical effects of treatment, investiga-
tor, visit, and treatment-by-visit interaction, as well as the 
continuous ﬁ  xed covariates of baseline score and baseline 
score-by-visit interaction. Type III sums-of-squares for the 
LS mean were used.
Treatment-emergent adverse events (TEAEs) were deﬁ  ned 
as events that ﬁ  rst occurred or worsened after randomization 
as compared with the maximum prerandomization severity. 
Events were reported using preferred terms for Version 9.1 
of MedDRA® (Medical Dictionary for Regulatory Activities) 
terminology.39
Unless otherwise speciﬁ  ed, “baseline” refers to the last 
nonmissing observation at or before the randomization visit 
(Visit 2, Week 0), and “endpoint” refers to the last nonmiss-
ing observation in the time period of analysis. The baseline 
used for determination of elevated blood pressure (BP) 
was the maximum prerandomization observation. When 
the investigator sites were used in the analyses, the sites 
having fewer than eight randomly assigned patients with a 
nonmissing value for baseline-to-endpoint change in the BPI 
average pain score were pooled and considered a single site. 
If a pooled site still had fewer than eight randomly assigned 
patients, these patients were pooled with the smallest remain-
ing site. This pooling procedure continued until every site 
used in the analyses had at least eight patients with data for 
change in the BPI average pain score.
All statistical analyses were performed using SAS®, 
Version 9.1.3 (SAS Institute Inc., Cary, NC, USA), running on 
a UNIX® system using SAS® Drug Development. Throughout 
this article, the term “signiﬁ  cant” indicates statistical signiﬁ  -
cance, and “mean” refers to LS mean, except for demographic 
and clinical characteristics at baseline and for laboratory tests, 
for which it refers to the arithmetic mean.
Results
Patient disposition
A total of 330 patients who met the entry criteria were 
randomly assigned to duloxetine 60 mg QD (N = 162) or 
placebo (N = 168) (Figure 2). A signiﬁ  cant difference was 
seen in rates of patients discontinuing due to lack of efﬁ  cacy 
(duloxetine, 12 [7.4%], placebo 25 [14.9%], P = 0.036).
Baseline demographic and clinical 
characteristics
The majority of the patients were female (93.3%) and 
Caucasian (90.9%), followed by Hispanic (7.6%), and African 
descent (0.9%). The mean (SD) age of the enrolled patients 
was 50.5 (10.7) years, and 22.4% of the enrolled patients had 
current MDD. No signiﬁ  cant differences among treatment 
groups were observed in any of the patient demographics or 
clinical characteristics (Table 1).
Efﬁ  cacy
Although the co-primary efﬁ  cacy measures of mean change 
in the BPI average pain score from baseline to endpoint International Journal of General Medicine 2008:1 95
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and the mean PGI-I at endpoint showed greater numerical 
improvement for duloxetine- than placebo-treated patients, 
the differences between the treatment groups were not 
statistically signiﬁ  cant (Table 2). For these, and several other 
variables, a signiﬁ  cant treatment-by-investigator interaction 
was observed (Table 2). The nature of the interaction 
was investigated, and it could not be clearly explained by 
country-speciﬁ  c or geographic region (United States vs 
Europe) effects. The duloxetine group improved signiﬁ  cantly 
more than the placebo group at all visits through Week 8 on 
both co-primary measures (BPI average pain score: Week 1 
P   0.001, Week 2 P   0.001, Week 4 P = 0.001, Week 6 
P = 0.002, Week 8 P = 0.015; PGI-I: Week 1 P = 0.043, 
Week 2 P = 0.005, Week 4 P = 0.014, Week 6 P = 0.003, 
Week 8 P = 0.007) as well as at Week 18 (P = 0.014) for 
the BPI average pain score, and Weeks 18 (P = 0.008), 
23 (P = 0.002), and 27 (P = 0.003) for the PGI-I, from the 
repeated measures analyses. Duloxetine-treated patients had 
signiﬁ  cantly greater AUC of pain relief (mean AUC = 270.07) 
than placebo-treated patients (mean AUC = 185.25; P = 0.010) 
(Table 2). Compared with the placebo group, the duloxetine 
group had a signiﬁ  cantly greater improvement from baseline 
to endpoint in the BPI least pain score (mean change: dulox-
etine −1.22, placebo −0.73, P = 0.046) and average interfer-
ence score (mean change: duloxetine −1.69, placebo −1.03, 
P = 0.009). In addition, signiﬁ  cant between-group differ-
ences were observed in the FIQ pain score (mean change: 
duloxetine –1.69, placebo −1.06, P = 0.030), CGI-S (mean 
change: duloxetine −0.57, placebo −0.28, P = 0.011), MFI 
mental fatigue score (mean change: duloxetine −0.99, placebo 
−0.03, P = 0.023), and BDI-II total score (mean change: 
duloxetine −3.42, placebo −1.45, P = 0.017) (Table 2).
Duloxetine (n = 162)
Screening
Phase
Double-
blind
Therapy
Phase
(27 Weeks)
Discontinued
in Double-blind Therapy Phase
(n = 61)
Reason:
￿ Adverse Event (30)
￿ Patient Decision (5)
￿ Protocol Violation (9)
￿ Lost to follow up (4)
￿ Sponsor Decision (1)
Completed
Double-blind
Therapy Phase
(n = 101)
Patients Randomly
Assigned
(N = 330)
Placebo
(n = 168)
Completed
Double-blind
Therapy Phase
(n = 103)
Discontinued
in Double-blind Therapy Phase
(n = 65)
Reason:
￿ Adverse Event (19)
￿ Lack of Efficacy (25)
￿ Patient Decision (9)
￿ Protocol Violation (5)
￿ Lost to follow up (6)
￿ Physician Decision (1)
￿ Lack of Efficacy (12)
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Analysis of the BPI average pain severity score response 
rates (deﬁ  ned as  50% reduction from baseline to endpoint) 
revealed no signiﬁ  cant differences for the duloxetine group 
(29.1% [46/158], P = 0.455) compared with the placebo 
group (25.1% [42/167]). Analysis of the response rates at 
endpoint, based on a  30% reduction in the BPI average 
pain severity score, also revealed no signiﬁ  cant difference 
between the duloxetine (38.0% [60/158]; P = 0.355) and 
placebo groups (32.9% [55/167]). Sustained response was 
deﬁ  ned as  50% reduction from baseline to endpoint in 
the BPI average pain severity, with a  50% reduction from 
baseline at an earlier visit, and with at least a 30% reduction 
from baseline at every visit with data in between. Analysis 
of the BPI average pain severity score sustained response 
showed no signiﬁ  cant difference for the duloxetine group 
(23.4% [37/158], P = 0.272) compared with the placebo 
group (18.0% [30/167]).
For therapy-by-subgroup evaluation of the mean change 
in the BPI average pain score from baseline to endpoint, 
there was no signiﬁ  cant interaction by age (P = 0.523), 
sex (P = 0.929), race (P = 0.382), diagnosis of MDD 
(P = 0.496) and secondary diagnosis of anxiety (P = 0.152). 
Among patients with a diagnosis of MDD, the mean 
change (SE) from baseline for duloxetine-treated patients 
was −1.34 (0.42) and in placebo-treated patients was −0.48 
(0.46). For patients who did not have a diagnosis of MDD, 
Table 1 Demographic and clinical characteristics at baseline
Variable Duloxetine 60/120 mg QD
N = 162
Placebo N = 168 P value
Age (years), mean (SD) 50.75 (10.05) 50.23 (11.35) 0.723
Sex
  Female, n (%) 149 (91.98) 159 (94.64) 0.382
  Male, n (%) 13 (8.02) 9 (5.36)
Race (origin)
  Caucasian, n (%) 150 (92.59) 150 (89.29) 0.555
  African, n (%) 2 (1.23) 1 (0.60)
  Hispanic, n (%) 10 (6.17) 15 (8.93)
  Native American, n (%) 0 1 (0.60)
  West Asian, n (%) 0 1 (0.60)
Weight (kg), mean (SD) 77.71 (16.79) 77.03 (19.24) 0.739
Diagnosis of MDD
  No, n (%) 126 (77.78) 130 (77.38) 1.00
  Yes, n (%) 36 (22.22) 38 (22.62)
Secondary diagnosis of anxiety
  No, n (%) 152 (98.06) 165 (98.80) 0.675
  Yes, n (%) 3 (1.94) 2 (1.20)
Previous antidepressant use
  No, n (%) 91 (56.17) 96 (57.14) 0.912
  Yes, n (%) 71 (43.83) 72 (42.86)
BPI average pain score, mean (SD) 6.58 (1.52) 6.43 (1.48) 0.380
FIQ total score, mean (SD) 49.55 (11.28) 50.62 (12.47) 0.380
Mean tender point threshold, mean (SD) 2.46 (0.92) 2.31 (0.74) 0.092
Count of low threshold, mean (SD) 16.38 (2.90) 16.81 (2.10) 0.128
CGI-S, mean (SD) 3.81 (1.20) 3.79 (1.26) 0.747
PGI-S, mean (SD) 3.97 (1.32) 3.84 (1.36) 0.388
HAMD17 total score, mean (SD) 9.32 (5.27) 9.31 (5.41) 0.865
  Non-MDD patients, mean (SD) 7.98 (4.27) 7.81 (4.48) 0.621
  MDD patients, mean (SD) 13.92 (5.85) 14.39 (5.24) 0.625
Notes: Some percentages do not add up to 100 due to rounding. For some variables, not all patients had data.
Abbreviations: QD, once daily; SD, standard deviation; MDD, major depressive disorder; BPI, Brief Pain Inventory; FIQ, Fibromyalgia Impact Questionnaire; CGI-S, Clinical 
Global Impressions of Severity; PGI-S, Patient’s Global Impressions of Severity; HAMD17, 17-item Hamilton Depression Rating Scale.International Journal of General Medicine 2008:1 97
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the mean change (SE) from baseline for duloxetine-treated 
patients was −1.60 (0.23) and in placebo-treated patients 
was −1.20 (0.22). There was a significant therapy-
by-previous antidepressant use interaction (P = 0.029). 
Among patients with previous antidepressant use, the mean 
change (SE) in the BPI average pain score for duloxetine-
treated patients was −1.85 (0.29) and in placebo-treated 
patients was −0.65 (0.27). For patients without previous 
antidepressant use, the mean change (SE) for duloxetine-
treated patients was −1.56 (0.29) and in placebo-treated 
patients was −1.51 (0.27).
Health outcomes and quality of life
Duloxetine-treated patients had significantly greater 
improvements, compared with placebo-treated patients in 
the SF-36 mental component summary score (mean change: 
duloxetine 3.37, placebo 0.79, P = 0.026), and SF-36 mental 
health score (mean change: duloxetine 6.63, placebo 1.19, 
P = 0.005) (Table 3).
Safety
For the 117 duloxetine-treated patients who continued past 
Week 13, the number of patients who stayed on duloxetine 
Table 2 Least-squares (LS) mean change from baseline to endpoint or at endpoint: efﬁ  cacy measures
Duloxetine
60/120 mg QD
Placebo
N LS mean 
change (SE)
N LS mean 
change (SE)
Duloxetine–placebo 
difference (95% CI)
P   Value Therapy-
by-investigator 
interaction 
P   Value
BPI average pain score 158 −1.62 (0.20) 167 −1.13 (0.19) −0.49 (−0.99, 0.01) 0.053 0.015
BPI worst pain score 158 −1.75 (0.22) 167 −1.25 (0.21) −0.49 (−1.04, 0.05) 0.077 0.019
BPI least pain score 158 −1.22 (0.19) 167 −0.73 (0.18) −0.49 (−0.97, −0.01) 0.046 0.114
BPI pain right now score 158 −1.68 (0.21) 167 −1.16 (0.20) −0.52 (−1.05, 0.01) 0.054 0.261
BPI average interference 158 −1.69 (0.20) 167 −1.03 (0.19) −0.66 (−1.16, −0.17) 0.009 0.139
Mean tender point threshold 148 0.40 (0.09) 159 0.18 (0.08) 0.22 (−0.00, 0.44) 0.055 0.002
Count of low threshold 148 −1.50 (0.30) 159 −0.92 (0.28) −0.58 (−1.32, 0.16) 0.121  0.001
FIQ total score 153 −7.96 (1.35) 163 −5.81 (1.29) −2.15 (−5.57, 1.28) 0.218 0.088
FIQ fatigue score 154 −0.94 (0.23) 163 −0.97 (0.22) 0.03 (−0.54, 0.60) 0.919 0.741
FIQ rested score 154 −1.09 (0.23) 163 −1.06 (0.22) −0.03 (−0.61, 0.54) 0.916 0.779
FIQ physical impairment score 154 −0.02 (0.18) 163 −0.06 (0.17) 0.03 (−0.43, 0.49) 0.892 0.106
FIQ pain score 154 −1.69 (0.22) 163 −1.06 (0.22) −0.63 (−1.20, −0.06) 0.030 0.054
CGI-S 156 −0.57 (0.09) 164 −0.28 (0.08) −0.29 (−0.51, −0.07) 0.011 0.003
MFI general fatigue 152 −0.33 (0.30) 162 −0.37 (0.29) 0.03 (−0.73, 0.80) 0.930 0.090
MFI physical fatigue 152 −0.48 (0.30) 162 −0.29 (0.29) −0.19 (−0.97, 0.58) 0.619 0.281
MFI mental fatigue 153 −0.99 (0.33) 161 −0.03 (0.31) −0.96 (−1.79, −0.13) 0.023 0.417
MFI reduced motivation 152 −0.27 (0.32) 162 −0.07 (0.31) −0.20 (−1.01, 0.61) 0.629 0.213
MFI reduced activity 151 −0.19 (0.34) 162 0.03 (0.33) −0.21 (−1.09, 0.66) 0.632 0.158
HAMD17 total score 143 −2.04 (0.40) 158 −1.70 (0.37) −0.34 (−1.35, 0.66) 0.503 0.639
BDI-II total score 154 −3.42 (0.63) 164 −1.45 (0.61) −1.97 (−3.58, −0.36) 0.017 0.591
PGI-Ia 158 3.43 (0.13) 165 3.72 (0.12) −0.30 (−0.62, 0.03) 0.073 0.004
AUC of pain relief  b 162 270.07 (25.19) 168 185.25 (24.42) 84.82 (20.81, 148.8) 0.010 0.049
Notes: aFor PGI-I, endpoint was analyzed, and the baseline used as a covariate was the PGI-S; bAUC of pain relief is a summary measure of change in the BPI average pain 
score over time, but is not a change from baseline to endpoint.
Abbreviations: QD, once daily; N, number of patients who had a baseline score (PGI-S for analysis of the PGI-I) and at least one nonmissing postbaseline score for that 
particular variable; SE, standard error; BPI, Brief Pain Inventory; FIQ, Fibromyalgia Impact Questionnaire; CGI-S, Clinical Global Impressions of Severity; MFI, Multidimensional 
Fatigue Inventory; HAMD17, 17-item Hamilton Depression Rating Scale; BDI-II, Beck Depression Inventory-II; PGI-I, Patient’s Global Impressions of Improvement;   AUC, area 
under the curve; SE, standard error; PGI-S, Patient’s Global Impressions of Severity.International Journal of General Medicine 2008:1 98
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60 mg QD were 19 (16.2%) and those who escalated were 
98 (83.8%). The mean (SD) average prescribed daily dose 
between Weeks 13 and 27 for patients who escalated (N = 97) 
was 113.4 (12.6) mg.
Of the 330 randomly assigned patients, 145/162 
(89.5%) duloxetine- and 137/168 (81.5%) placebo-treated 
patients reported at least 1 TEAE (P = 0.043). TEAEs 
that occurred in  5% of duloxetine- and twice the rate of 
placebo-treated patients are shown in Table 4. There were 
no TEAEs that occurred at a signiﬁ  cantly higher rate in the 
placebo- compared with the duloxetine-treated group. No 
deaths occurred during the study. No signiﬁ  cant difference 
between treatment groups was observed in the percentage 
of patients with at least 1 serious adverse event (SAE). 
During the study, 4 patients (2.5%) in the duloxetine-treated 
group experienced the SAEs of arthralgia, gait disturbance, 
pseudomonal lung infection, muscular weakness, par-
aesthesia, and pseudoneurologic symptom (1 [0.6%] for 
each event), and 4 (2.4%) patients in the placebo-treated 
group experienced the SAEs of arthralgia, abdominal pain 
upper, cystocele, and noncardiac chest pain (1 [0.6%] for 
each event). A total of 49 (14.8%) patients discontinued 
during the therapy phase due to an adverse event, with no 
signiﬁ  cant difference between the duloxetine- and placebo-
treated groups (duloxetine, 30 [18.5%]; placebo, 19 [11.3%]; 
P = 0.088). The most common ( 1%) adverse events 
reported as reasons for discontinuation in the duloxetine-
treated group were nausea (3 [1.9%]), dizziness, diarrhea, 
lethargy, somnolence, and vomiting (2 [1.2%] for each 
event), and in the placebo-treated group, dizziness and 
irritability (2 [1.2%] for each event).
There were signiﬁ  cant differences between the duloxetine- 
and the placebo-treated groups for mean change in alkaline 
phosphatase (mean change [SD] units/liter: duloxetine = 2.38 
[12.02], placebo = −2.45 [9.94]; P   0.001), alanine 
transaminase/serum glutamate pyruvate transaminase (mean 
change [SD], units/liter: duloxetine, 6.97 [50.29]; placebo, 
−0.93 [5.70]; P = 0.038), total bilirubin (mean change 
[SD], micromole/liter: duloxetine, −0.35 [2.97]; placebo, 
0.27 [2.54]; P = 0.020), cholesterol (mean change [SD], 
micromole/liter: duloxetine −0.04 [0.71]; placebo, −0.23 
[0.75]; P = 0.016), and uric acid (mean change [SD], 
Table 3 Least-squares (LS) mean change from baseline to endpoint: health outcome and quality-of-life measures
Duloxetine
60/120 mg QD
Placebo
N LS mean 
change (SE)
N LS mean 
change (SE)
Duloxetine–placebo 
difference (95% CI)
P Value Therapy-
by-investigator 
interaction
P Value
SDS global functional impairment 
total score
143 −2.34 (0.59) 160 −2.35 (0.56) 0.01 (−1.48, 1.51) 0.986 0.012
SDS work/school score 128 −0.93 (0.23) 144 −0.77 (0.21) −0.16 (−0.73, 0.41) 0.581 0.074
SDS social life/leisure activities score 147 −0.75 (0.21) 161 −0.72 (0.20) −0.03 (−0.57, 0.50) 0.903 0.118
SDS family life/home responsibilities 
score
147 −0.82 (0.21) 161 −0.82 (0.20) −0.00 (−0.54, 0.53) 0.997 0.007
SF-36 mental component summary 146 3.37 (0.91) 162 0.79 (0.85) 2.58 (0.30, 4.86) 0.026 0.175
SF-36 physical component summary 146 2.61 (0.67) 162 2.06 (0.63) 0.55 (−1.13, 2.24) 0.519 0.616
SF-36 bodily pain 148 10.35 (1.61) 162 6.82 (1.52) 3.53 (−0.51, 7.58) 0.086 0.193
SF-36 general health 147 5.16 (1.37) 162 2.49 (1.29) 2.67 (−0.77, 6.11) 0.128 0.570
SF-36 mental health 148 6.63 (1.52) 162 1.19 (1.43) 5.44 (1.63, 9.25) 0.005 0.224
SF-36 physical functioning 148 4.66 (1.50) 162 3.52 (1.41) 1.14 (−2.60, 4.89) 0.548 0.130
SF-36 role-emotional 146 10.45 (3.51) 162 4.27 (3.30) 6.18 (−2.63, 14.99) 0.168 0.085
SF-36 role-physical 147 10.45 (2.92) 162 5.60 (2.75) 4.85 (−2.47, 12.18) 0.193 0.013
SF-36 social functioning 148 5.99 (2.04) 162 4.55 (1.92) 1.44 (−3.67, 6.56) 0.579 0.579
SF-36 vitality 148 5.99 (1.64) 162 2.86 (1.55) 3.13 (−0.98, 7.25) 0.135 0.119
EQ-5D index score 146 0.10 (0.03) 160 0.05 (0.02) 0.05 (−0.01, 0.12) 0.109 0.436
Abbreviations: QD, once daily; N, number of patients who had a baseline score and at least one nonmissing postbaseline score for that particular variable; SE, standard error; 
SDS, Sheehan Disability Scale; SF-36, 36-item Short-Form Health Survey; EQ-5D, EuroQol Questionnaire-5 dimensions.International Journal of General Medicine 2008:1 99
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micromole/liter: duloxetine, −19.51 [43.50]; placebo, 3.91 
[42.92]; P   0.001).
Signiﬁ  cant treatment group differences were observed 
for mean change in sitting pulse rate (mean change [SE], 
beats/minute: duloxetine, 1.08 [0.87]; placebo, −1.64 
[0.84]; P = 0.016) and diastolic BP (mean change [SE], 
mmHg: duloxetine, 1.68 [0.85]; placebo, −1.46 [0.82]; 
P = 0.004). Three patients in each group experienced 
sustained elevation of BP (deﬁ  ned as systolic BP  140 
and  10 mmHg increase for at least 3 consecutive visits 
or diastolic BP  90 and  10 mmHg increase for at least 3 
consecutive visits), and the between-group difference was 
not signiﬁ  cant.
No signiﬁ  cant differences were observed between treat-
ment groups in mean change for corrected QT intervals using 
either Fridericia’s (QTcF), Bazett’s (QTcB), or the regression 
correction, and in the QRS interval. Signiﬁ  cant differences 
were observed between treatment groups in mean change in 
the PR interval (millisecond) from baseline to endpoint (mean 
change [SE]: duloxetine, –4.51 [1.20]; placebo, 1.97 [1.14]; 
P   0.001), QT interval (mean change [SE]: duloxetine, 
–4.27 [1.98]; placebo, 3.79 [1.87]; P = 0.002), RR interval 
(mean change [SE]: duloxetine, –36.00 [10.73]; placebo, 
14.51 [10.15]; P   0.001), and heart rate (mean change 
[SE] beats/minute: duloxetine, 2.87 [0.83]; placebo, –0.99 
[0.79]; P   0.001).
Discussion
In this phase-III, parallel, double-blind, 27-week, placebo-
controlled trial, no statistically signiﬁ  cant differences were 
observed between the treatment groups for the co-primary 
efﬁ  cacy measures (mean change in BPI average pain score 
from baseline to endpoint and mean PGI-I score at end-
point). For these, and several other variables, there was a 
statistically signiﬁ  cant treatment-by-investigator interaction 
(shown in Tables 2 and 3); therefore, the overall effect must 
be interpreted with caution. The nature of the interaction 
was investigated, and it could not be clearly explained by 
country-speciﬁ  c or geographic region (United States vs 
Europe) effects. The duloxetine group improved signiﬁ  cantly 
more than the placebo group at all visits through Week 8, 
as well as at Week 18, for the BPI average pain score and 
at all visits through Week 8, as well as Weeks 18, 23, and 
27 for the PGI-I.
The magnitude of the treatment benefit reported in 
the current study for the mean change in the BPI aver-
age pain score from baseline to endpoint and the PGI-I 
score at endpoint are not consistent with those reported 
in the previous clinical trials evaluating duloxetine in the 
treatment of ﬁ  bromyalgia.25,26 Most previous pain stud-
ies were 12 weeks or less in duration.23–26 In the previous 
phase-II, 12-week, randomized, placebo-controlled trial of 
duloxetine in which male and female patients with ACR-
deﬁ  ned primary ﬁ  bromyalgia were randomized to dulox-
etine 60 mg BID or placebo,25 duloxetine was superior to 
placebo on the BPI average pain score and PGI-I score. The 
previous phase-III study of female patients randomized to 
duloxetine 60 mg QD, 60 mg BID, or placebo26 also showed 
superiority of duloxetine compared with placebo on the BPI 
average pain score and the PGI-I score. The treatment effects 
for duloxetine compared with placebo for the co-primary 
efﬁ  cacy variables of the BPI average pain score and the PGI-
Improvement in this study were smaller than were observed 
in three other placebo-controlled studies of duloxetine. Also, 
the treatment effects for almost all secondary measures 
were smaller than in the previous studies. Rater training 
and other aspects of study conduct were similar for all the 
studies. One difference between this and previous studies is 
the statistically signiﬁ  cant treatment-by-investigator inter-
actions for the mean change in both co-primary variables 
and for many secondary measures in this study. Eighteen 
of the 36 investigators had small numbers of patients with 
data and were pooled into one investigator for analysis, for 
which the results were numerically in favor of duloxetine 
compared with placebo for both the BPI average pain score 
and the PGI-Improvement. However, for the remaining 
18 investigators, the results were numerically in favor of 
placebo compared with duloxetine for 10 investigators for 
Table 4 Treatment-emergent adverse events that occurred in 
 5% of duloxetine patients and at least twice the rate in placebo 
patients
Duloxetine
N = 162, n (%)
Placebo
N = 168, n (%)
P  Value*
Nausea 44 (27.2) 16 (9.5)  0.001
Headache 35 (21.6) 18 (10.7) 0.010
Dry mouth 32 (19.8) 9 (5.4)  0.001
Diarrhoea 26 (16.0) 11 (6.5) 0.008
Constipation 26 (16.0) 9 (5.4) 0.002
Hyperhidrosis 17 (10.5) 4 (2.4) 0.003
Arthralgia 10 (6.2) 5 (3.0) 0.193
Somnolence 12 (7.4) 2 (1.2) 0.006
Dyspepsia 9 (5.6) 4 (2.4) 0.164
Sleep disorder 9 (5.6) 4 (2.4) 0.164
Note: *Fisher’s exact P value.
Abbreviation: N, number of randomly assigned patients.International Journal of General Medicine 2008:1 100
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the BPI and for seven investigators for the PGI-Improvement. 
This was the ﬁ  rst study to include patients in the United States 
and also elsewhere (Germany, Spain, Sweden, and the United 
Kingdom). The interaction did not appear to be attributable 
to country or region (United States vs Europe). In spite of 
the treatment reversals for a large number of investigators, 
which dilutes the overall treatment effect, there were large 
beneﬁ  ts for duloxetine compared with placebo for some 
investigators, resulting in an overall numerical advantage 
for duloxetine for both the BPI average pain score and 
the PGI-Improvement, indicating the supportive nature of 
this study for a treatment beneﬁ  t for duloxetine in the treat-
ment of patients with ﬁ  bromyalgia.
Compared with placebo-treated patients, patients treated 
with duloxetine had signiﬁ  cantly greater AUC of pain relief 
and experienced greater improvements in the BPI least pain 
score and average interference score. In addition, duloxetine-
treated patients experienced signiﬁ  cantly greater improve-
ments, compared with placebo, in the FIQ pain item, MFI 
mental fatigue dimension, CGI-S, and BDI-II total scores. 
Approximately 22% of all patients had MDD at baseline, 
which is consistent with the prevalence of depression con-
current with ﬁ  bromyalgia (22%–45%).4,40–43 No treatment-
by-MDD interaction was observed for mean change in the 
BPI average pain score. In the present study there was no 
signiﬁ  cant therapy-by-sex interaction, suggesting that the 
effect of duloxetine compared with placebo was similar 
in males and females. A previous clinical trial evaluating 
duloxetine in the treatment of ﬁ  bromyalgia demonstrated a 
signiﬁ  cant effect on reduction of pain in women but not in 
men,25 although this discrepancy might have been be due to 
the small number of men enrolled in the study.
Generalizability of these results is limited by the fact 
that patients in this study were carefully selected to exclude 
psychiatric and medical co-morbidities, and could be 
less severely ill than ﬁ  bromyalgia patients in the general 
population.
In summary, in patients with fibromyalgia, with or 
without MDD, duloxetine 60/120 mg/day improved average 
pain severity and self-reported global improvement through 
week 8 (and some subsequent visits), but not at endpoint, rela-
tive to placebo. Consistent with earlier trials of duloxetine in 
the treatment of ﬁ  bromyalgia,25,26 in this study, duloxetine was 
safely administered, and relatively well tolerated (considering 
the length of the trial) by most patients. Although duloxetine 
failed to demonstrate signiﬁ  cant improvement over placebo 
on the co-primary outcome measures, in this supportive 
study, duloxetine demonstrated signiﬁ  cant improvement 
compared with placebo on a number of secondary measures 
that are important in assessing treatment efﬁ  cacy in patients 
with ﬁ  bromyalgia.
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